{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:54:21Z","timestamp":1774896861825,"version":"3.50.1"},"reference-count":63,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Outstanding Youth Science Fund Project of China","award":["82122016"],"award-info":[{"award-number":["82122016"]}]},{"name":"National Outstanding Youth Science Fund Project of China","award":["2017YFA0105804"],"award-info":[{"award-number":["2017YFA0105804"]}]},{"name":"National Key Research and Development Program of China","award":["82122016"],"award-info":[{"award-number":["82122016"]}]},{"name":"National Key Research and Development Program of China","award":["2017YFA0105804"],"award-info":[{"award-number":["2017YFA0105804"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Long-term systemic glucocorticoids and non-specific immunosuppressants remain the mainstay of treatment for refractory scleritis, and result in serious side-effects and repeated inflammation flares. To assess the efficacy and safety of additional adalimumab, patients diagnosed with refractory non-infectious scleritis were enrolled. They were assigned to the conventional-therapy (CT, using systemic glucocorticoids and other immunosuppressants) group or the adalimumab-plus-conventional-therapy (ACT) group according to the treatments they received. The primary outcome was time to achieve sustained remission, assessed by a reduction in modified McCluskey\u2019s scleritis scores. Other outcomes included changes in McCluskey\u2019s scores, scleritis flares, best-corrected visual acuity, and spared glucocorticoid dosage. Patients in the ACT group achieved faster remission than those in the CT group, as the median periods before remission were 4 months vs. 2.5 months (p = 0.016). Scleritis flares occurred in 11\/11 eyes in the CT group and 5\/12 eyes in the ACT group (p = 0.005). Successful glucocorticoid sparing was realized in both groups, but the ACT group made it faster. No severe adverse events were observed. Data suggest that adalimumab plus conventional therapy could shorten the time to remission, reduce disease flares, and accelerate glucocorticoid withdrawal compared with conventional therapy alone.<\/jats:p>","DOI":"10.3390\/jcm11226686","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:24:10Z","timestamp":1668399850000},"page":"6686","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis"],"prefix":"10.3390","volume":"11","author":[{"given":"Binyao","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizhao","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuening","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daquan","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Tao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-6362","authenticated-orcid":false,"given":"Wenru","family":"Su","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China"},{"name":"Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Scleritis","volume":"50","author":"Okhravi","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/APO.0000000000000341","article-title":"Current Approach for the Diagnosis and Management of Noninfective Scleritis","volume":"10","author":"Majumder","year":"2020","journal-title":"Asia-Pacific J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br. J. Ophthalmol."},{"key":"ref_4","first-page":"43","article-title":"Clinical Characteristics of a Large Cohort of Patients with Scleritis and Episcleritis","volume":"119","author":"Molina","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/09273948.2016.1241282","article-title":"Clinical Features and Complications of Scleritis in Chinese Patients","volume":"26","author":"Yang","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_6","first-page":"393","article-title":"Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies","volume":"9","author":"Vignesh","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_7","first-page":"742","article-title":"Incidence of eye disease in cases of connective tissue disease","volume":"94","author":"Williamson","year":"1974","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10384-018-0600-y","article-title":"Clinical characteristics and ocular complications of patients with scleritis in Japanese","volume":"62","author":"Tanaka","year":"2018","journal-title":"JPN J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2012.08.005","article-title":"Visual Outcome, Treatment Results, and Prognostic Factors in Patients with Scleritis","volume":"120","author":"Wieringa","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","article-title":"Scleritis: Immunopathogenesis and molecular basis for therapy","volume":"35","author":"Wakefield","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108078","DOI":"10.1016\/j.exer.2020.108078","article-title":"Current insights in the pathogenesis of scleritis","volume":"197","author":"Vergouwen","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40123-021-00393-8","article-title":"Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review","volume":"10","author":"Sota","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: A new treatment perspective","volume":"35","author":"Fidelix","year":"2015","journal-title":"Int. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous Humor and Serum Tumor Necrosis Factor-\u03b1 in Clinical Uveitis","volume":"33","author":"Lacomba","year":"2001","journal-title":"Ophthalmic Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets\u2019 Disease-Associated Uveitis: A Systematic Review and Meta-Analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/17460441.2021.1846516","article-title":"Preclinical discovery and development of adalimumab for the treatment of rheu-matoid arthritis","volume":"16","author":"Pelechas","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14712598.2020.1733524","article-title":"Current and emerging biologics for the treatment of juvenile idiopathic arthritis","volume":"20","author":"Cimaz","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with me-ta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2032s disease and ul-cerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12348-016-0107-y","article-title":"Refractory necrotizing scleritis successfully treated with adalimumab","volume":"6","author":"Lawuyi","year":"2016","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10067-009-1368-8","article-title":"Successful treatment of severe nodular scleritis with adalimumab","volume":"29","author":"Restrepo","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_23","first-page":"16","article-title":"Bilateral Posterior Scleritis: Analysis of 18 Cases from a Large Cohort of Posterior Scleritis","volume":"24","author":"Lavric","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1442-9071.1991.tb00663.x","article-title":"Prediction of response to treatment in patients with scleritis using a standardised scoring system","volume":"19","author":"McCluskey","year":"1991","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/bjophthalmol-2017-311610","article-title":"Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial","volume":"102","author":"Huang","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1167\/iovs.05-0981","article-title":"Visual acuities \"hand motion\" and \"counting fingers\" can be quantified with the freiburg visual acuity test","volume":"47","author":"Feltgen","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standard-ization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/postgradmedj-2011-130282","article-title":"Scleritis: Presentations, disease associations and management","volume":"88","author":"Sims","year":"2012","journal-title":"Postgrad. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: Results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.5414\/CP202171","article-title":"Effectiveness of infliximab, ada-limumab and golimumab for non-infectious refractory uveitis in adults","volume":"53","author":"Cortes","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients","volume":"119","author":"Salom","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","article-title":"A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2032s disease: A comparative 4-week study","volume":"50","author":"Markomichelakis","year":"2011","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive noninfectious uveitis controlled by cortico-steroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/1623847","article-title":"Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study","volume":"2019","author":"Bitossi","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","article-title":"Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: Focus on Beh\u00e7et\u2019s syndrome","volume":"28","author":"Silvestri","year":"2020","journal-title":"Inflammopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0161-6420(99)00719-8","article-title":"Scleritis: A clinicopathologic study of 55 cases","volume":"106","author":"Riono","year":"1999","journal-title":"Ophthalmology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2172-10-15","article-title":"Tumor necrosis factor-alpha induced expression of matrix metalloproteinase-9 through p21-activated Kinase-1","volume":"10","author":"Zhou","year":"2009","journal-title":"BMC Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000090010","article-title":"Expression of Tumor Necrosis Factor Alpha and Matrix Metalloproteinase-9 in Surgically Induced Necrotizing Scleritis","volume":"38","author":"Seo","year":"2006","journal-title":"Ophthalmic Res."},{"key":"ref_41","first-page":"653","article-title":"Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts","volume":"150","author":"Lloyd","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jlb.61.6.667","article-title":"Expression of TNF-alpha by human plasma cells in chronic in-flammation","volume":"61","author":"Visvanathan","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"ref_43","first-page":"e395","article-title":"Interleukin-22 serum levels are elevated in active scleritis","volume":"94","author":"Molins","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nishio, Y., Taniguchi, H., Takeda, A., and Hori, J. (2021). Immunopathological Analysis of a Mouse Model of Arthritis-Associated Scleritis and Implications for Molecular Targeted Therapy for Severe Scleritis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010341"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-020-00296-y","article-title":"The haplotypes of various TNF related genes associated with scleritis in Chinese Han","volume":"14","author":"Gao","year":"2020","journal-title":"Hum. Genom."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert Panel Recommendations for the Use of Anti\u2013Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders","volume":"121","author":"Jabs","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","article-title":"A three-centre experience with adalimumab for the treatment of non-infectious uveitis","volume":"97","author":"Dobner","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","article-title":"Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Beh\u00e7et\u2019s uveitis with vasculitis","volume":"93","author":"Yang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"609148","DOI":"10.3389\/fphar.2021.609148","article-title":"The Efficacy of Adalimumab as an Initial Treatment in Patients with Beh\u00e7et\u2019s Retinal Vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"799427","DOI":"10.3389\/fmed.2021.799427","article-title":"Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy","volume":"8","author":"Yang","year":"2022","journal-title":"Front. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21037\/atm-22-2668","article-title":"Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-na\u00efve Vogt-Koyanagi-Harada disease pa-tients","volume":"10","author":"Yang","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-620X.91271","article-title":"Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis","volume":"4","author":"Bawazeer","year":"2011","journal-title":"Oman J. Ophthalmol."},{"key":"ref_53","first-page":"2288","article-title":"Adalimumab-induced remission of anterior scleritis: A very rare late mani-festation of Takayasu arteritis","volume":"54","author":"Akhtar","year":"2015","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for Ocular Inflammation","volume":"25","author":"Durrani","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/09273940802023786","article-title":"Biologic Response Modifier Therapy for Psoriatic Ocular Inflammatory Disease","volume":"16","author":"Huynh","year":"2008","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjophthalmol-2018-312767","article-title":"Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: An 8-year prospective surveillance study","volume":"105","author":"Sharma","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4103\/ijo.IJO_966_20","article-title":"Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India","volume":"68","author":"Biswas","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3109\/09273948.2013.863944","article-title":"Treatment of Chronic, Noninfectious, Nonnecrotizing Scleritis with Tumor Necrosis Factor Alpha Inhibitors","volume":"22","author":"Ragam","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: Results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","article-title":"A Standardized Grading System for Scleritis","volume":"118","author":"Sen","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_61","first-page":"1138","article-title":"Effectiveness of TNF-\u03b1 blockade in the treatment of refractory non-infectious scleritis: A multicentre study","volume":"38","author":"Fabiani","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0039-6257(88)90093-8","article-title":"Posterior scleritis","volume":"32","author":"Benson","year":"1988","journal-title":"Surv. Ophthalmol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2032s disease","volume":"72","author":"Burmester","year":"2012","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6686\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:26Z","timestamp":1760145266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":63,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11226686"],"URL":"https:\/\/doi.org\/10.3390\/jcm11226686","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}